Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aardvark Therapeutics, Inc. (AARD : NSDQ)

• Company Description    Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $12.60 Daily Weekly Monthly 20 Day Moving Average: 82,617 shares Shares Outstanding: 21.70 (millions) Market Capitalization: $273.37 (millions) Beta: 52 Week High: $19.58 52 Week Low: $4.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.92% 9.66% 12 Week 80.00% 51.40% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4370 La Jolla Village Drive Suite 1050 - San Diego,CA 92122 USA ph: 858-225-7696 fax: - investorrelations@aardvarktherapeutics.com https://aardvarktherapeutics.com

• General Corporate Information    Officers Tien-Li Lee - Chief Executive Officer and Director Bryan Jones - Chief Operating Officer Nelson Sun - Chief Financial Officer Roy D. Baynes - Director Susan E. Graf - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 002942100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 21.70 Most Recent Split Date: (:1) Beta: Market Capitalization: $273.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 35.22% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.81 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - 25.86 12/31/24 - 15.05 Quick Ratio 06/30/25 - - 03/31/25 - 25.86 12/31/24 - 15.05 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 6.95 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©